LifeMD Inc expected to post a loss of 1 cent a share - Earnings Preview

LifeMD

01/08/2025 21:05

LifeMD Inc LFMD.OQ LFMD.O is expected to  show a rise in quarterly revenue when it reports  results on August 5 for the period ending June 30 2025

The New York City-based  company is expected to report a 31.0% increase in revenue to $66.343 million from $50.66 million a year ago, according to the mean estimate from 7 analysts, based on LSEG data.The company's guidance on May 6 2025, for the period ended June 30, was for revenue between $65.00 million and $67.00 million.

​LSEG's mean analyst estimate for LifeMD Inc is for a loss of 1 cent per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for LifeMD Inc is $14.00, about 25.6% above its last closing price of $10.41

The company's guidance on May 6 2025 for the period ended June 30 was for Earnings before Interest, Taxes, Depreciation and Amortization of between USD65 million and USD9 million.

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-0.06
-0.05
0.01
Beat
118.9
Dec. 31 2025
-0.07
-0.05
-0.02
Beat
61.1
Sep. 30 2024
-0.12
-0.12
-0.14
Missed
-18​
Jun. 30 2024
-0.14
-0.12
-0.19
Missed
-52
​​Mar. 31 2024
-0.16
-0.15
-0.19
Missed
-23.4
Dec. 31 2023
-0.12
-0.14
-0.12
Beat
14.3​
Sep. 30 2023
-0.15
-0.15
-0.20
Missed
-29
Jun. 30 2023
-0.10
-0.10
-0.23
Missed
-122.6

This summary was machine generated August 1 at 20:05 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)